Equities Analysts Set Expectations for TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a report issued on Wednesday, June 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.70) for the year, down from their previous forecast of ($0.67). The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Travere Therapeutics' FY2026 earnings at $0.21 EPS.

A number of other equities research analysts also recently issued reports on the company. JPMorgan Chase & Co. increased their price target on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Bank of America upped their target price on Travere Therapeutics from $29.00 to $31.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Canaccord Genuity Group raised their price target on Travere Therapeutics from $45.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Scotiabank reaffirmed an "outperform" rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Finally, HC Wainwright upgraded shares of Travere Therapeutics to a "buy" rating and set a $30.00 price objective on the stock in a research note on Wednesday, June 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $32.14.

Travere Therapeutics Stock Down 2.9%

Shares of TVTX opened at $14.50 on Monday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 12 month low of $6.80 and a 12 month high of $25.29. The firm's 50 day moving average is $16.87 and its 200-day moving average is $18.53. The stock has a market capitalization of $1.29 billion, a PE ratio of -3.54 and a beta of 0.75.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The business had revenue of $81.73 million for the quarter, compared to the consensus estimate of $77.44 million. During the same period in the prior year, the company posted ($1.76) earnings per share. Travere Therapeutics's revenue was up 83.3% compared to the same quarter last year.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Travere Therapeutics during the fourth quarter worth $31,000. Sterling Capital Management LLC raised its position in Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after purchasing an additional 2,115 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Travere Therapeutics during the 1st quarter worth about $62,000. Gen Wealth Partners Inc bought a new stake in shares of Travere Therapeutics in the 4th quarter valued at about $73,000. Finally, KBC Group NV acquired a new stake in shares of Travere Therapeutics in the first quarter valued at about $75,000.

Insider Activity at Travere Therapeutics

In other news, CEO Eric M. Dube sold 18,924 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $398,350.20. Following the sale, the chief executive officer now directly owns 419,173 shares in the company, valued at approximately $8,823,591.65. The trade was a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christopher R. Cline sold 1,784 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,553.20. Following the completion of the transaction, the chief financial officer now directly owns 93,126 shares of the company's stock, valued at $1,960,302.30. This represents a 1.88% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,527 shares of company stock valued at $473,814. 4.19% of the stock is owned by insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.